aβ40

Begacestat (GSI-953) is a potent and selective gamma-secretase inhibitor (γ-secretase) that inhibits Amyloid-beta production with nanomolar potency, selectively inhibits cleavage of APP in cellular level Notch cleavage assays, reverses situational memory deficits, and can be used to study Alzheimer's disease.

MK-0752, a γ-secretase inhibitor, reduces Aβ40 production(IC50=5 nM).

DC-Chol hydrochloride(DC-Cholesterol hydrochloride) inhibited the formation of Aβ40 fibrils under appropriate experimental conditions and significantly inhibited amyloid formation from oxidized hCT in a dose-dependent manner.DC-Chol hydrochloride induces an improved and balanced immunity, which could contribute to hepatitis B vaccine research.

RO4929097 (RG-4733), a γ secretase inhibitor (IC50: 4 nM), inhibits cellular processing of Aβ40 and Notch (EC50: 14/5 nM).

Verubecestat (MK-8931) (MK-8931) is an effective and specific β-secretase inhibitor and β-site APP-cleaving enzyme 1 inhibitor or BACE1 protein inhibitor.

Tau/Aβ40 aggregation-IN-1 (Compound 20) functions as an inhibitor for tau and Aβ 40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively [1].

NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM.

QO-40 is a KCNQ2/3 potassium channels activator.

M40 acetate is a potent, non-selective galanin receptor antagonist (Ki values are 1.82 and 5.1 nM at GAL1 and GAL2 respectively) that inhibits galanin (1-29) binding in rat brain in vitro (IC50 = 3 - 15 nM). Attenuates the antidepressant effects of fluoxetine and blocks galanin-induced food intake in vivo. Also exhibits weak partial agonist activity at peripheral GAL2 receptors at doses > 100 nM.

Citrullinated amyloid-β(1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) that has undergone citrullination at the Arg5 position. Compared to the unmodified β-Amyloid (1-40), it exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of twisted parallel β-sheets.

GPR40 Agonist 2 is a compound that functions as a GPR40 agonist and is utilized in diabetes research.

GPR40 Activator 1 is a potent activator of GPR40 for the treatment of type 2 diabetes.

GPR40 Activator 2 is a highly effective activator of the GPR40 receptor.

GPR40/FFAR1 modulator 1 is a Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1) agonist and allosteric modulator.

GPR40 agonist 1 is an effective new GPR40 agonist (EC50s: 17 nM and 2 nM for rGPR40 and hGPR40).

NF-56-EJ40 is an effective and highly selective antagonist of human SUCNR1 with an IC50 of 25 nM and a Ki of 33 nM.

EN40, as a covalent ligand, is a selective inhibitor of aldehyde dehydrogenase 3A1 (IC50: 2 uM).

E3 Ligase Ligand-linker Conjugate 131 serves as a crucial intermediate in the synthesis of the complete PROTAC molecule CPD-39; it represents a (conjugate of E3 ligase Ligand and linker). This compound is vital for bridging the components necessary for forming the active PROTAC structure.

MS40 is a WDR5 PROTAC that selectively degrades WDR5 and serves as a novel degrader for immune-modulating compounds (IMiDs), including the new substrates CRBN and Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40 facilitates the degradation of WDR5, resulting in the dissociation of the MLL/KMT2A complex from chromatin, thereby reducing H3K4me2 levels. In vitro, MS40 inhibits the growth of primary leukemia patient cells, and in vivo, it suppresses the expansion of patient-derived xenografts.

NEP(1-40), N-terminal uncapped, is an analog of NEP(1-40) without acetylation at the N-terminus. NEP(1-40) acts as a peptide antagonist of the Nogo-66 receptor (NgR).

BTK-IN-40 (compound 375) is an inhibitor of BTK.

KRAS inhibitor-40 (Compound 41) is an inhibitor of KRAS, disrupting the KRAS G12C-BRAF complex and suppressing the phosphorylation of the downstream ERK signaling pathway. This compound also inhibits the proliferation of tumor cells with various KRAS mutations, exhibiting antitumor activity.

Tyrosinase-IN-40 (Compound 9r) is a competitive inhibitor of tyrosinase, boasting an IC50 value of 17.02 µM and a Ki value of 14.87 µM. This compound also exhibits antioxidant activity and can be utilized in studies related to melanin.

JAK-IN-40 (Compound 46) is an inhibitor of JAK, effectively targeting JAK1, JAK2, and JAK3 with IC50 values of 0.022, 0.759, and 1.601 μM, respectively. It reduces the phosphorylation of STAT3 and inhibits the proliferation of cancer cells Ba/F3 and JAK1-TEL Ba/F3 with GI50 values of 0.614 μM and 0.193 μM. JAK-IN-40 arrests cell cycle progression at the G2/M phase in H1975 and H2087 cells, leading to apoptosis. Additionally, JAK-IN-40 exhibits a synergistic anti-tumor effect when used in combination with Osimertinib.